MLS PHARMA
ActiveSummary
MLS PHARMA has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €437,939 and a net result of €197,555. Equity is growing by about 33% per year across the filed financial years. The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
06-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Highest result from 2022 to 2025net €197,555 ▲20.2%
Operating result €251,731, net result €197,555, both a record.
08-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 8 days late
2024
23-09
Gazette deed
Permanent representative: Iris CarsauRegistered-office move3 facts ▸
Gazette deed
Permanent representative: Iris Carsau
Registered-office move3 facts ▸
- General meeting, 05-08-2024
- Registered-office move, Rue des Dix Journaux 10 boîte 21, 4121 Neupré
- Permanent representative, Iris Carsau
26-08
NBB filing
Annual accounts filed
financial year 2023 · micro format · 26 days late
2023
31-12
Financial
Equity above €200,000equity €250,994 ▲88%
A profit in every financial year since 2022 builds equity to €250,994.
30-08
NBB filing
Annual accounts filed
financial year 2022 · micro format · 30 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
1 of 2 deeds read
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.